1609391-90-3
Chemical Structure
Tyk2-IN-7
- CAS No.: 1609391-90-3
- Formula:C18H15D3N6O3S
- Molecular Weight:401.46
IUPAC Name: N-(methyl-d3)-4-((2-(methylsulfonyl)phenyl)amino)-6-(pyridin-2-ylamino)pyridazine-3-carboxamide
InChIKey: KUHISBZXQSKCLH-FIBGUPNXSA-N
SMILES: O=C(NC([2H])([2H])[2H])C1=NN=C(NC2=CC=CC=N2)C=C1NC3=CC=CC=C3S(=O)(C)=O
Biological Activity: Tyk2-IN-7 is an orally active TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tyk2-IN-7 | 99.58% | Tyk2-IN-7 is an orally active TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tyk2-IN-14 | Tyk2-IN-14 is a Tyk2 inhibitor that regulates IFNα and IL-23 by inhibiting Tyk2-mediated signal transduction. Tyk2-IN-14 exhibits an IC50 of 0.08 μM against the IL-23 Kit225 reporter gene and an IC50 of 0.09 μM against the IFNα Kit225 reporter gene. IL-23 modulator-1 is applicable to the research of inflammatory diseases and autoimmune diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Moslin R, et al. Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2). J Med Chem. 2019 Oct 24;62(20):8953-8972. [Content Brief]
- [2]. Wrobleski ST, et al. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. J Med Chem. 2019 Oct 24;62(20):8973-8995. [Content Brief]
